Acute Lymphoblastic Leukemia Clinical Trial
Official title:
Motor Proficiency And Physical Activity in Adult Survivors of Childhood ALL
The primary goal of this study is to provide comprehensive and objective information on impairments of musculoskeletal health, sensory function, and fitness among a large group of childhood ALL survivors, and to define high risk groups by assessing treatment factors that contribute to impaired function. This study includes a direct, objective evaluation of musculoskeletal function, sensory capacity, fitness, and physical activity patterns among adults who were treated for childhood ALL at St. Jude Children's Research Hospital (SJCRH) between 1980 and 1999. Among 899 ALL survivors, all of whom are eligible for an institutionally funded clinical study of medical late effects, the study will recruit 364 to participate in our evaluations. The study will also recruit 364 individuals for a comparison group, frequency matching on race/ethnicity, age and gender.
The study will focus on the following primary objectives:
1. Enumerate the prevalence of musculoskeletal, sensory, and fitness impairments among
adult survivors of childhood ALL. The study hypothesizes that adult survivors of
childhood ALL will have a higher prevalence of musculoskeletal, sensory and fitness
impairments than a control group frequency matched on race/ethnicity, age, and gender.
2. Evaluate the association between personal and treatment factors and musculoskeletal,
sensory and fitness impairments. The study hypothesizes that:
- Female gender, younger age at diagnosis, and cranial radiation will be associated
with decreased lean body mass.
- Female gender, younger age at diagnosis, and type of glucocorticoid (dexamethasone
vs. prednisone) treatment will be associated with muscle weakness.
- Sensory loss will vary as a function of age, with participants diagnosed at 12+
years of age demonstrating vincristine related sensory loss, and those diagnosed
at <12 years of age demonstrating dexamethasone and/or intrathecal methotrexate
related sensory loss.
- Fitness impairments will be evident in participants who received 100 mg/m2+ of
anthracyclines.
The study will focus on the secondary objectives:
1. Compare physical activity patterns between adult survivors of childhood ALL and a
frequency matched control group. The study hypothesizes that adult survivors of
childhood ALL will demonstrate lower levels of physical activity as measured with an
activity monitor (accelerometer), and will report lower levels of overall physical
activity, when compared to members of the comparison group.
2. Describe the association between habitual physical activity and energy expenditure
among ALL survivors. The study hypothesizes that activity levels, measured with the
accelerometer, will be positively correlated with energy expenditure, measured using
the doubly labeled water technique.
3. Explore the associations between musculoskeletal and sensory health, and physical
activity patterns among adult survivors of childhood ALL. The study hypothesizes that
adult survivors of childhood ALL with lower proportions of lean muscle mass and/or
sensory loss indicating peripheral neuropathy will demonstrate the lowest levels of
physical activity.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT05772000 -
Clinical Significance of Occult Central Nervous System Localization
|
||
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06308588 -
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT05579132 -
A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Withdrawn |
NCT02815059 -
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
|
Phase 1 | |
Completed |
NCT00390793 -
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT04488237 -
Vitamin D and Methotrexate Adverse Effects
|
||
Completed |
NCT02544438 -
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 |